ReNeuron Group PLC RNUGF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.09
- Bid/Ask
- $0.00 / $980,001.10
- Market Cap
- $62,891.14
- Volume/Avg
- 7,345 / 1,893
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.21
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes the human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and U.S. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 32
- Website
- https://www.reneuron.com
Valuation
|
Metric
|
RNUGF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.02 |
Price/Sales | 0.21 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
RNUGF
|
|---|---|
Quick Ratio | 1.51 |
Current Ratio | 1.51 |
Interest Coverage | −347.56 |
Quick Ratio
RNUGF
Profitability
|
Metric
|
RNUGF
|
|---|---|
Return on Assets (Normalized) | −45.11% |
Return on Equity (Normalized) | −92.62% |
Return on Invested Capital (Normalized) | −88.23% |
Return on Assets
RNUGF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Bhgjxfpx | Qhvgy | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Jrlkqjkpq | Tmdpdp | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Pbbtrgggj | Rmwqnct | $118.7 Bil | |||
| Moderna Inc
MRNA
| Mwdyjjdc | Cxsm | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ctpydyhs | Wgcgfg | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Zrwgbkn | Mrvt | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Yyqddrcmr | Slzfj | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Qvhjygvh | Sslvy | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Cnqbnybd | Wpj | $15.0 Bil | |||
| Incyte Corp
INCY
| Xjpbhmmc | Knxxdrb | $13.5 Bil |